ALEXION PHARMACEUTICALS INC's gross profit margin for the fourth quarter of its fiscal year 2014 is essentially unchanged when compared to the same period a year ago. Even though it increased sales and net income significantly, the company was unable to grow at a faster pace than its industry competitors. ALEXION PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 3.95 which clearly shows the ability to cover any short-term cash needs. ALXN managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 38.61% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY14||Q4 FY13|
|Net Sales ($mil)||599.48||441.91|
|Net Income ($mil)||153.33||-18.99|
|Balance Sheet||Q4 FY14||Q4 FY13|
|Cash & Equiv. ($mil)||1961.57||1514.85|
|Total Assets ($mil)||4201.96||3317.7|
|Total Debt ($mil)||164.6||145.23|
|Profitability||Q4 FY14||Q4 FY13|
|Gross Profit Margin||94.7||90.22|
|Return on Assets||15.63||7.62|
|Return on Equity||19.89||10.61|
|Debt||Q4 FY14||Q4 FY13|
|Share Data||Q4 FY14||Q4 FY13|
|Shares outstanding (mil)||199.06||196.96|
|Div / share||0.0||0.0|
|Book value / share||16.59||12.09|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1260420.0||1130352.0|
BUY. ALEXION PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 43.77 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 19.92. For additional comparison, its price-to-book ratio of 11.04 indicates a significant premium versus the S&P 500 average of 2.81 and a discount versus the industry average of 12.09. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|ALXN 56.17||Peers 43.77||ALXN 56.95||Peers 58.29|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
ALXN is trading at a significant premium to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ALXN is trading at a valuation on par to its peers.
|ALXN 25.47||Peers 28.54||ALXN 0.72||Peers 0.56|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
ALXN is trading at a premium to its peers.
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
ALXN trades at a significant premium to its peers.
|ALXN 11.04||Peers 12.09||ALXN 158.73||Peers 19.68|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ALXN is trading at a valuation on par with its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ALXN is expected to have an earnings growth rate that significantly exceeds its peers.
|ALXN 16.32||Peers 222.77||ALXN 43.98||Peers 99.50|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ALXN is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ALXN significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV